by last | Nov 13, 2022 | 2022, Past Events
Philogen will attend the TIDES Europe in Vienna in November 2022. Samuele Cazzamalli, Head of Small Molecules Therapeutics at Philogen, will give a lecture entitled “Non-internalizing Small Molecule-Drug Conjugates and Radioligand Therapeutics targeting Fibroblast...by Lisa Nadal | Nov 11, 2022 | 2022, Past Events, Scientific
The study describes the discovery of GCPIII as the protein responsible for the accumulation of conventional PSMA targeting agents in healthy organs. More detailsby Lisa Nadal | Nov 7, 2022 | 2022, Press Releases, Scientific
Philogen announces publication in Chem (Cell Press) on novel affinity matured OncoFAP ligands isolated from DNA-Encoded Chemical Libraries. The novel OncoFAP ligands show a prolonged residence time in Fibroblast Activation Protein (FAP) positive tumors. The...by Lisa Nadal | Oct 19, 2022 | 2022, Press Releases, Scientific
The study shows excellent tumor uptake of the novel OncoFAP-MMAE Small Molecule-Drug Conjugates (SMDCs) with high and selective release of the cytotoxic MMAE payload at the tumor site. OncoFAP-based pro-drugs are currently being developed for the imaging and therapy...by last | Sep 28, 2022 | 2022, Past Events
Philogen held a virtual briefing on 29 September 2022 at 10:00 ET / 15:00 BST / 16:00 CEST following the Board of Directors’ approval of the Half-Yearly Financial Report as of 30 June 2022. Prof. Dr. Dario Neri, Chief Executive Officer, Dr. Laura Baldi, Chief...by last | Jul 6, 2022 | 2022, Past Events
Philogen announces its attendance at the Peptide Therapeutic Forum 2022. Samuele Cazzamalli, Head of Small Molecule Therapeutics at Philogen, is giving a lecture entitled “Small Molecule Therapeutics as an alternative to Peptide Therapeutics: a clean strategy to...